247 related articles for article (PubMed ID: 1618247)
1. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
Korting HC; Vieluf D; Kerscher M
Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
[TBL] [Abstract][Full Text] [Related]
2. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.
Schäfer-Korting M; Korting HC; Kerscher MJ; Lenhard S
Clin Pharmacol Ther; 1993 Oct; 54(4):448-56. PubMed ID: 8222488
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
Cossmann M; Welzel J
Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
[TBL] [Abstract][Full Text] [Related]
4. Topical glucocorticoids and thinning of normal skin as to be assessed by ultrasound.
Korting HC
Curr Probl Dermatol; 1993; 21():114-21. PubMed ID: 8299364
[No Abstract] [Full Text] [Related]
5. Different skin thinning potential of equipotent medium-strength glucocorticoids.
Korting HC; Unholzer A; Schäfer-Korting M; Tausch I; Gassmueller J; Nietsch KH
Skin Pharmacol Appl Skin Physiol; 2002; 15(2):85-91. PubMed ID: 11867964
[TBL] [Abstract][Full Text] [Related]
6. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study.
Queille-Roussel C; Paul C; Duteil L; Lefebvre MC; Rapatz G; Zagula M; Ortonne JP
Br J Dermatol; 2001 Mar; 144(3):507-13. PubMed ID: 11260007
[TBL] [Abstract][Full Text] [Related]
7. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
Serup J; Holm P
Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness.
Lévy J; Gassmüller J; Schröder G; Audring H; Sönnichsen N
Skin Pharmacol; 1994; 7(4):231-6. PubMed ID: 8024805
[TBL] [Abstract][Full Text] [Related]
9. Influence of glucocorticoid substances and the vehicle on skin irritancy: determination by profilometry.
Korting HC
Curr Probl Dermatol; 1993; 21():140-6. PubMed ID: 8299367
[No Abstract] [Full Text] [Related]
10. Side effects of topical glucocorticoids.
Mills CM; Marks R
Curr Probl Dermatol; 1993; 21():122-31. PubMed ID: 8299365
[No Abstract] [Full Text] [Related]
11. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Kerscher MJ; Hart H; Korting HC; Stalleicken D
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):187-9. PubMed ID: 7620686
[TBL] [Abstract][Full Text] [Related]
12. 0.05% clobetasol 17-propionate cream and ointment but not the corresponding 0.1% triamcinolone acetonide preparations increase skin surface roughness: a possible dissociation of unwanted epidermal and dermal effects.
Kerscher MJ; Korting HC; Mehringer L; Mätzig R
Skin Pharmacol; 1996; 9(2):120-3. PubMed ID: 8722606
[TBL] [Abstract][Full Text] [Related]
13. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound.
Kerscher MJ; Korting HC
Acta Derm Venereol; 1992; 72(3):214-6. PubMed ID: 1357864
[TBL] [Abstract][Full Text] [Related]
14. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis.
Blum G; Yawalkar S
J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1153-6. PubMed ID: 1757607
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis.
Yawalkar SJ; Schwerzmann L
J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1163-6. PubMed ID: 1757610
[TBL] [Abstract][Full Text] [Related]
16. Commercial glucocorticoid formulations and skin dryness. Could it be caused by the vehicle?
Korting HC; Kerscher M; Vieluf D; Mehringer L; Megele M; Braun-Falco O
Acta Derm Venereol; 1991; 71(3):261-3. PubMed ID: 1678236
[TBL] [Abstract][Full Text] [Related]
17. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy.
Kragballe K; Barnes L; Hamberg KJ; Hutchinson P; Murphy F; Møller S; Ruzicka T; Van De Kerkhof PC
Br J Dermatol; 1998 Oct; 139(4):649-54. PubMed ID: 9892908
[TBL] [Abstract][Full Text] [Related]
18. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis.
Kerscher MJ; Korting HC
Skin Pharmacol; 1992; 5(2):77-80. PubMed ID: 1637562
[TBL] [Abstract][Full Text] [Related]
19. An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis.
Callender VD; Young CM; Haverstock CL; Carroll CL; Feldman SR
Cutis; 2005 Jun; 75(6):317-21. PubMed ID: 16047868
[TBL] [Abstract][Full Text] [Related]
20. Local tolerability of topically applied methylprednisolone aceponate.
Kecskés A; Jahn P; Lange L
J Am Acad Dermatol; 1993 May; 28(5 Pt 1):786-8. PubMed ID: 8496430
[No Abstract] [Full Text] [Related]
[Next] [New Search]
